Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543322 | 1.00 | GAA (0.47) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL15200264 | 1.00 | GAA (0.47) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| Hydrochloric Acid SCHEMBL27282102 | 0.98 | GAA (0.46) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL4544933 | 0.94 | TP53 (0.46) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL6238118 | 0.92 | PLG (0.48) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL12055465 | 0.87 | CHRNB2 (0.42) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL14296565 | 0.87 | CHRNB2 (0.42) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL5888214 | 0.87 | CHRNB2 (0.42) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL14305169 | 0.86 | TP53 (0.46) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 | |
| SCHEMBL17118123 | 0.86 | TP53 (0.46) | GAATP53ALDH1A1SMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2022081995-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20210179720-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
| US-10738242-B2 | Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element | DIC CORPORATION (JP) | 2020-08-11 | — | — | US | disclosed |
| US-9939555-B2 | Cinnamic acid derivative, polymer thereof, and liquid crystal alignment layer comprising cured product thereof | DIC CORPORATION (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9939555-B2 | Cinnamic acid derivative, polymer thereof, and liquid crystal alignment layer comprising cured product thereof | DIC CORPORATION (JP) | 2018-04-10 | — | — | US | disclosed |
| WO-2017173408-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9708535-B2 | Liquid crystal alignment layer | DIC CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | GAA 916/4885TP53 969/4885ALDH1A1 166/4885 |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | GAA 2099/4885TP53 425/4885ALDH1A1 2146/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GAA 916/4885TP53 969/4885ALDH1A1 166/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | GAA 1100/4885TP53 1761/4885ALDH1A1 2855/4885 |
| US-10738242-B2 | Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element | PYM1, ZYX, CRY1 | GAA 4039/4885TP53 4787/4885ALDH1A1 2197/4885 |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | GAA 3924/4885TP53 1128/4885ALDH1A1 3166/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | GAA 4050/4885TP53 1349/4885ALDH1A1 3084/4885 |
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | GAA 1043/4885TP53 4245/4885ALDH1A1 4302/4885 |
| US-20210179720-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | GAA 970/4885TP53 94/4885ALDH1A1 4316/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | GAA 1100/4885TP53 1761/4885ALDH1A1 2855/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GAA 916/4885TP53 969/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.